Canadian Pricing Body Sharpens Its Teeth
This article was originally published in Scrip
Companies doing business in Canada are likely to see new action to drive down medicine prices. Concerned by spiraling drug prices and its place in an increasingly complex pricing and reimbursement environment, the Patented Medicine Prices Review Board (PMPRB) has published a new three-year strategic plan which will address how it can better contribute to lower prices and sustainable healthcare, although nearer-term measures could be on the cards too.
You may also be interested in...
Companies operating in Canada could face pharmacoeconomic evaluations to decide if drugs are over-priced as well as a requirement to disclose information that could impair the confidentiality of pricing agreements.
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.
Early discussions between companies and multiple regulators could drive greater alignment among jurisdictions.